NASDAQ:NPSP NPS Pharmaceuticals (NPSP) Stock Price, News & Analysis → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free NPSP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get NPS Pharmaceuticals alerts: Email Address Ad Porter & CompanyThe Worst is Yet to Come…Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly.Click here to stream this controversial exposé now. About NPS Pharmaceuticals Stock (NASDAQ:NPSP)NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company’s second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.Read More Ad Porter & CompanyThe Worst is Yet to Come…Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly.Click here to stream this controversial exposé now. NPSP Stock News HeadlinesNovember 14, 2023 | forbes.comArena PharmaceuticalsOctober 18, 2023 | investing.comNPSP Historical DataMarch 31, 2023 | thestreet.comNPS Stock Gaps Down On Today's Open (NPSP)February 13, 2023 | msn.comHow to reclaim withdrawn but unclaimed amount from National Pension System (NPS) accountDecember 15, 2022 | msn.comHow much money is held under National Pension System (NPS): State-wise data hereOctober 6, 2022 | msn.comNPS proposes systematic lump sum withdrawal plan for pensioners; invites suggestions till 19 OctoberSeptember 21, 2022 | thestreet.comNPS Pharma: Bullish Options Trade Into the Gattex FDA PanelSeptember 9, 2022 | msn.comNPS Calculator: Want Rs 75,000 monthly pension post retirement? Here’s how much you need to investJuly 18, 2022 | thestreet.comEnzon and NPS Pharma Call Off MergerJune 28, 2022 | msn.comNPS Pension Calculator: Now you can get Rs 2 lakh per month, here's howMay 4, 2022 | thestreet.comCramer's 'Mad Money' Recap: The Winning FormulaFebruary 20, 2022 | forbes.comKrispy Kreme Doughnuts (DNUT)January 7, 2022 | thestreet.comEuropean Stocks Rebound as Pharma Deals Renew ConfidenceOctober 26, 2021 | finance.yahoo.comCelgene and NPS Pharmaceuticals Shares Surge on Positive FDA NewsSee More Headlines Receive NPSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NPS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/18/2015Today5/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:NPSP CUSIP62936P10 CIK890465 Webwww.npsp.com Phone+1-908-4505300FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report NPSP Stock Analysis - Frequently Asked Questions How were NPS Pharmaceuticals' earnings last quarter? NPS Pharmaceuticals Inc (NASDAQ:NPSP) announced its earnings results on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.06 by $0.08. The biopharmaceutical company earned $66.70 million during the quarter, compared to the consensus estimate of $69.30 million. What other stocks do shareholders of NPS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NPS Pharmaceuticals investors own include Gilead Sciences (GILD), General Electric (ge), Intercept Pharmaceuticals (ICPT), Pharmacyclics (PCYC), Pfizer (PFE), Alkermes (ALKS), 3D Systems (DDD), FireEye (FEYE) and GW Pharmaceuticals (GWPH). This page (NASDAQ:NPSP) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account Before It’s Too LateWeiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NPS Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.